Literature DB >> 18758298

Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.

Hubert Vesselle1, Alexander Salskov, Eric Turcotte, Linda Wiens, Rodney Schmidt, C Diana Jordan, Eric Vallières, Douglas E Wood.   

Abstract

INTRODUCTION: We compared primary non-small cell lung cancer (NSCLC) F-fluorodeoxyglucose (FDG) uptake at positron emission tomography (PET) to tumor histologic features and Ki-67 proliferation index. This large, prospectively-recruited patient cohort has previously been analyzed based on differences in FDG uptake across stage groups; the current analysis adds further dimensions to this characterization.
MATERIALS AND METHODS: One hundred seventy-eight patients with potentially-resectable NSCLC were scanned with FDG PET before therapy. A partial volume correction algorithm was used to correct FDG uptake values for their dependence on tumor size. Primary tumor resection specimens, core biopsies, and biopsies of metastatic lymph nodes were used to assess each tumor's NSCLC histologic subtype, degree of differentiation, and Ki-67 proliferation index.
RESULTS: Bronchioalveolar carcinomas were found to have lower FDG uptake at PET and lower Ki-67 scores than any other histologic subtype. Non-bronchioalveolar adenocarcinomas had lower FDG uptake and Ki-67 scores than squamous cell carcinomas or large cell undifferentiated carcinomas. Better differentiated NSCLCs had lower FDG uptake and Ki-67 scores than more poorly differentiated NSCLCs. There was a significant positive correlation between FDG uptake and Ki-67 scores. Partial volume correction increased the strength of this correlation, while also diminishing the strong positive correlation between FDG uptake and tumor size.
CONCLUSIONS: There are significant differences in NSCLC FDG uptake across histologic subtypes and differentiation groups. These differences parallel nearly identical differences in Ki-67 scores, implying that differences in NSCLC tumor cell proliferation may give rise to commensurate differences in tumor glucose metabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18758298     DOI: 10.1097/JTO.0b013e31818307a7

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  55 in total

1.  The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours.

Authors:  Bernadette G Dijkman; Olga C J Schuurbiers; Dennis Vriens; Monika Looijen-Salamon; Johan Bussink; Johanna N H Timmer-Bonte; Miranda M Snoeren; Wim J G Oyen; Henricus F M van der Heijden; Lioe-Fee de Geus-Oei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-10       Impact factor: 9.236

2.  [¹⁸F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case.

Authors:  Hubert H Chuang; Ferhat Deniz; Kanishka Sircar; Camilo Jimenez; Carlos Rubin De Celis; Christopher G Wood; Mouhammed Amir Habra
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

3.  FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Christos Colovos; Kei Suzuki; Nabil P Rizk; Mark P S Dunphy; Emily C Zabor; Camelia S Sima; Akihiko Yoshizawa; William D Travis; Valerie W Rusch; Prasad S Adusumilli
Journal:  Ann Surg Oncol       Date:  2012-05-30       Impact factor: 5.344

4.  Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.

Authors:  Kai-Hsiung Ko; Hsian-He Hsu; Tsai-Wang Huang; Hong-Wei Gao; Daniel H Y Shen; Wei-Chou Chang; Yi-Chih Hsu; Tsun-Hou Chang; Chi-Ming Chu; Ching-Liang Ho; Hung Chang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-23       Impact factor: 9.236

5.  Prognostic value of 18F-FDG uptake by regional lymph nodes on pretreatment PET/CT in patients with resectable colorectal cancer.

Authors:  Byung Hyun Byun; Sun Mi Moon; Ui Sup Shin; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

6.  Use of 18F-FDG PET/CT to predict short-term outcomes early in the course of chemoradiotherapy in stage III adenocarcinoma of the lung.

Authors:  Xiang-Rong Zhao; Yong Zhang; Yong-Hua Yu
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

7.  Autoclustering of Non-small Cell Lung Carcinoma Subtypes on (18)F-FDG PET Using Texture Analysis: A Preliminary Result.

Authors:  Seunggyun Ha; Hongyoon Choi; Gi Jeong Cheon; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2014-06-11

8.  High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.

Authors:  Kyuichi Kadota; Stefan S Kachala; Jun-Ichi Nitadori; Kei Suzuki; Mark P S Dunphy; Camelia S Sima; William D Travis; Valerie W Rusch; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2012-07       Impact factor: 15.609

9.  Associations between the standardized uptake value of (18)F-FDG PET/CT and demographic, clinical, pathological, radiological factors in lung cancer.

Authors:  Aysel Sunnetcioglu; Ahmet Arısoy; Yusuf Demir; Selami Ekin; Erkan Dogan
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 10.  18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy.

Authors:  Eric C Ford; Joseph Herman; Ellen Yorke; Richard L Wahl
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.